Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Preclinical data reported at ASN support utility of OP-1 in treating renal disease

Nov. 12, 1999

Novel agents for renal diseases with benzimidazole structure

Nov. 11, 1999

NeXstar research leads to identification of new target for treating renal disease

Nov. 11, 1999

P-selectin blocker SKK-60037 may help prevent progressive renal injuries

Nov. 9, 1999

Selectin ligand antagonist TBC-1269 attenuates renal ischemic reperfusion injury in rats

Nov. 9, 1999

Vasopressin antagonist VPA-985: summary of clinical data presented at ASN

Nov. 9, 1999

Antifibrotic agent pirfenidone slows the progression of glomerulosclerosis

Nov. 8, 1999

News from ASN: PDGF tyrosine kinase is a target for intervention in renal diseases

Nov. 8, 1999

Agents for urinary incontinence, pollakiuria in early development at Fujisawa

Nov. 4, 1999

U Penn researchers identify new target for treatment of erectile dysfunction

Nov. 2, 1999

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...